At the news
? BULLISHIMPACT 4/10 8-K filed Jul 7, 2026 at 08:15 ET
SAB Biotherapeutics announced that Breakthrough T1D awarded a grant to support the PRISE-hATG study evaluating SAB-142 in Stage 3 type 1 diabetes patients 100 days to 2 years from diagnosis. The investigator-led study extends the clinical program beyond the typical 100-day window and complements the ongoing Phase 2b SAFEGUARD trial. SAB BIO will co-fund the study; the grant amount was not disclosed.
- Breakthrough T1D awarded a grant to Dr. Michael Haller at University of Florida for the PRISE-hATG study of SAB-142.
- PRISE-hATG evaluates SAB-142 in Stage 3 T1D patients 100 days to 2 years from diagnosis, extending beyond the typical 100-day window.
- The study is randomized, double-blind, placebo-controlled and harmonized with the Phase 2b SAFEGUARD trial.
- SAB BIO will co-fund the study; grant amount not disclosed.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access